Page last updated: 2024-11-10

pactamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pactamycin: Antibiotic produced by Streptomyces pactum used as an antineoplastic agent. It is also used as a tool in biochemistry because it inhibits certain steps in protein synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5289124
CHEMBL ID458512
SCHEMBL ID197044
MeSH IDM0015738

Synonyms (28)

Synonym
u 15800
sk 27773
nsc-52947
ai3-51038
(5-((3-acetylphenyl)amino)-4-amino-3-(((dimethylamino)carbonyl)amino)-1,2-dihydroxy-3-(1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-hydroxy-6-methylbenzoate (1s-(1alpha,2beta,3alpha,3(r*),4alpha,5beta))-
2,6-cresotic acid, monoester with 3-(4-(m-acetylanilino)-5-amino-2,3-dihydroxy-1-(1-hydroxyethyl)-2-(hydroxymethyl)-3-methylcyclopentyl)-1,1-dimethylurea(van)
benzoic acid, 2-hydroxy-6-methyl-, (3-((3-acetylphenyl)amino)-4-amino-5-(((dimethylamino)carbonyl)amino)-1,2-dihydroxy-5-(1-hydroxyethyl)-2-methylcyclopentyl)methyl ester
benzoic acid, 2-hydroxy-6-methyl-, (5-((3-acetylphenyl)amino)-4-amino-3-(((dimethylamino)carbonyl)amino)-1,2-dihydroxy-3-(1-hydroxyethyl)-2-methylcyclopentyl)methyl ester, (1s-(1alpha,2beta,3alpha,3(r*),4alpha,5beta))-
nsc 52947
u-15800
pactamycin
NSC52947 ,
23668-11-3
PCY ,
CHEMBL458512
[(1s,2r,3r,4s,5s)-5-(3-acetylanilino)-4-amino-3-(dimethylcarbamoylamino)-1,2-dihydroxy-3-[(1s)-1-hydroxyethyl]-2-methylcyclopentyl]methyl 2-hydroxy-6-methylbenzoate
unii-18p04j5471
18p04j5471 ,
SCHEMBL197044
pactamycin [mi]
2,6-cresotic acid, monoester with 3-(4-(m-acetylanilino)-5-amino-2,3-dihydroxy-1-(1-hydroxyethyl)-2-(hydroxymethyl)-3-methylcyclopentyl)-1,1-dimethylurea
benzoic acid, 2-hydroxy-6-methyl-, ((1s,2r,3r,4s,5s)-5-((3-acetylphenyl)amino)-4-amino-3-(((dimethylamino)carbonyl)amino)-1,2-dihydroxy-3-((1s)-1-hydroxyethyl)-2-methylcyclopentyl)methyl ester
pactamycin, >=95% (hplc)
WVIUOSJLUCTGFK-JUJPXXQGSA-N
AKOS030623121
{(1s,2r,3r,4s,5s)-5-[(3-acetylphenyl)amino]-4-amino-3-[(dimethylcarbamoyl)amino]-1,2-dihydroxy-3-[(1s)-1-hydroxyethyl]-2-methylcyclopentyl}methyl 2-hydroxy-6-methylbenzoate
Q27252022
DTXSID801043235

Research Excerpts

Overview

Pactamycin is a structurally unique aminocyclitol antibiotic with broad-spectrum cell growth inhibitory activity. Pactamycin has antitumor and antimalarial properties.

ExcerptReferenceRelevance
"Pactamycin is a structurally unique aminocyclitol antibiotic with broad-spectrum cell growth inhibitory activity. "( Asymmetric Synthesis and Biological Activities of Pactamycin-Inspired Aminocyclopentitols.
Brumsted, CJ; Carpenter, EL; Indra, AK; Mahmud, T, 2018
)
2.18
"Pactamycin is an antibiotic produced by Streptomyces pactum with antitumor and antimalarial properties. "( Functional Characterization of 3-Aminobenzoic Acid Adenylation Enzyme PctU and UDP-N-Acetyl-d-Glucosamine: 3-Aminobenzoyl-ACP Glycosyltransferase PctL in Pactamycin Biosynthesis.
Eguchi, T; Hirayama, A; Kudo, F; Sato, S; Zhang, J, 2019
)
2.15
"Pactamycin is a bacteria-derived aminocyclitol antibiotic with a wide-range of biological activity. "( Interrogating the Tailoring Steps of Pactamycin Biosynthesis and Accessing New Pactamycin Analogues.
Abugrain, ME; Alani, A; Brumsted, CJ; Ishmael, JE; Kelly, JX; Li, Y; Lu, W; Mahmud, T; Osborn, AR; Serrill, JD, 2016
)
2.15
"Pactamycin is an aminocyclopentitol-derived natural product that has potent antibacterial and antitumor activities. "( Deciphering pactamycin biosynthesis and engineered production of new pactamycin analogues.
Flatt, PM; Ito, T; Kasanah, N; Lu, W; Mahmud, T; Miranda, C; Roongsawang, N; Shirasaka, N, 2009
)
2.17

Effects

ExcerptReferenceRelevance
"Pactamycin has a unique aminocyclitol core that is decorated with 3-aminoacetophenone, 6-methylsaliciate, and an N,N-dimethylcarbamoyl group."( Functional Characterization of 3-Aminobenzoic Acid Adenylation Enzyme PctU and UDP-N-Acetyl-d-Glucosamine: 3-Aminobenzoyl-ACP Glycosyltransferase PctL in Pactamycin Biosynthesis.
Eguchi, T; Hirayama, A; Kudo, F; Sato, S; Zhang, J, 2019
)
1.43
"Pactamycin has a unique aminocyclitol core that is decorated with 3-aminoacetophenone, 6-methylsaliciate, and an N,N-dimethylcarbamoyl group."( Functional Characterization of 3-Aminobenzoic Acid Adenylation Enzyme PctU and UDP-N-Acetyl-d-Glucosamine: 3-Aminobenzoyl-ACP Glycosyltransferase PctL in Pactamycin Biosynthesis.
Eguchi, T; Hirayama, A; Kudo, F; Sato, S; Zhang, J, 2019
)
1.43

Treatment

Pactamycin treatment allows completed proteins to be made yet lowers rRNA labeling. Anisomycin treatment does not show synthesis of complete proteins yet increases r RNA labeling.

ExcerptReferenceRelevance
"Pactamycin treatment also reduced the infectivity of T."( Biochemical requirements for intracellular invasion by Trypanosoma cruzi: protein synthesis.
Kierszenbaum, F; Lima, MF, 1982
)
0.99
"Pactamycin treatment allows completed proteins to be made yet lowers rRNA labeling, while anisomycin treatment does not show synthesis of complete proteins yet increases rRNA labeling."( Ribosome subunit to polysome ratios affect the synthesis of rRNA in Drosophila cells.
Pellegrini, M; Yamamoto, KK, 1990
)
1

Dosage Studied

ExcerptRelevanceReference
" Time-course and dose-response studies showed that the peptide specifically inhibited the translation of procollagen mRNA in preparations of human fibroblast RNA while not affecting the translation of globin mRNA or of other messenger RNAs in fibroblast RNA."( Regulation of protein synthesis: translational control by procollagen-derived fragments.
Bornstein, P; Goh, SH; Hörlein, D; McPherson, J, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID734205Antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR Green-based fluorescence assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734215Antibacterial activity against Escherichia coli ATCC 25922 after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734203Antimalarial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR Green-based fluorescence assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734207Cytotoxicity against human WI38 cells2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734211Antibacterial activity against Acinetobacter baumannii clinical isolate after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734214Antibacterial activity against Staphylococcus aureus ATCC 25923 after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734213Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734206Cytotoxicity against human MDA231 cells2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734204Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR Green-based fluorescence assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734212Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734209Cytotoxicity against human PC3 cells2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID734210Antibacterial activity against Enterococcus faecalis ATCC 29212 after 20 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID734208Cytotoxicity against human HCT116 cells2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Probing functional diversity in pactamycin toward antibiotic, antitumor, and antiprotozoal activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (199)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990124 (62.31)18.7374
1990's27 (13.57)18.2507
2000's9 (4.52)29.6817
2010's35 (17.59)24.3611
2020's4 (2.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.87 (24.57)
Research Supply Index5.31 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other197 (97.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]